Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

LIPID PL1

  Cat. No.:  DC80068  
Chemical Structure
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
PL1 is a novel biomimetic phospholipid. PL1 nanoparticle delivery of costimulatory receptor CD137 mRNA improved the immunotherapy with an anti-CD137 Ab to some extent in both tumor models with better results obtained in the B16F10 melanoma model as compared to the A20 lymphoma model.
Cas No.:
Chemical Name: LIPID PL1
Synonyms: PL-1, PL 1,LIPID-PL1
SMILES: O=C(OC(CC)CCCCC)CCCCCCCCN(CCCOP(=O)(OCC)OCC)CCCN(CCCCCCCCC(=O)OC(CC)CCCCC)CCCCCCCCC(=O)OC(CC)CCCCC
Formula: C61H121N2O10P
M.Wt: 1073.6
Purity: >95%
Sotrage: -20
Publication: Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy-By: Li, Wenqing; Zhang, Xinfu ; Zhang, Chengxiang; Yan, Jingyue; Hou, Xucheng ; Du, Shi; Zeng, Chunxi; Zhao, Weiyu; Deng, Binbin; McComb, David W. ; et al Nature Communications (2021), 12(1), 7264 | Language: English, Database: CAplus and MEDLINE
Description: PL1 is a novel biomimetic phospholipid. PL1 nanoparticle delivery of costimulatory receptor CD137 mRNA improved the immunotherapy with an anti-CD137 Ab to some extent in both tumor models with better results obtained in the B16F10 melanoma model as compared to the A20 lymphoma model.
References: Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy-By: Li, Wenqing; Zhang, Xinfu ; Zhang, Chengxiang; Yan, Jingyue; Hou, Xucheng ; Du, Shi; Zeng, Chunxi; Zhao, Weiyu; Deng, Binbin; McComb, David W. ; et al Nature Communications (2021), 12(1), 7264 | Language: English, Database: CAplus and MEDLINE
Cat. No. Product name Field of application
DC33580 DODMA DODMA, also known as MBN 305A is a a cationic lipid containing the unsaturated long-chain (18:1) oleic acid inserted at both the sn-1 and sn-2 positions. It has been used in the composition of lipospomes formulated as stable nucleic acid lipid particles that can encapsulate siRNA or other small molecules to be used for drug delivery
DC67981 Diamino lipid DAL4 Diamino lipid DAL4 is diamino lipid for the preparation of lipid nanoparticles (LNPs) encapsulated with mRNAs encoding cytokines including IL-12, IL-27 and GM-CSF. Diamino lipid DAL4 delivers mRNA to tumor cells to exert anti-tumor activity.
DC67563 S-Ac7-DOg S-Ac7-DOg​​ is an ​​ionizable lipid​​ engineered for optimized mRNA delivery to the retina, featuring a ​​sulfur-based ester bond​​ (S-Ac) and ​​dual oleyl glyceride chains​​ (DOg). Its pKa (~6.74) is finely tuned to enhance ​​endosomal escape​​ in acidic environments, enabling efficient cytosolic mRNA release. Unlike traditional lipids (e.g., C12-200, MC3), S-Ac7-DOg incorporates ​​biodegradable ester linkages​​ that hydrolyze intracellularly, minimizing lipid accumulation and reducing innate immune activation. In vitro, S-Ac7-DOg LNPs achieved >80% transfection efficiency in retinal cells (ARPE-19, MIO-M1) with ​​negligible cytokine secretion​​, outperforming MC3 and rivaling C12-200 while avoiding the latter’s high immunogenicity. In vivo, intravitreal delivery in mice showed ​​robust protein expression​​ in the optic nerve head (ONH) and Müller glia (75–100% of eyes), sustained for ≥7 days. Critically, it induced the ​​lowest immunogenicity​​ among tested lipids: minimal leukocyte infiltration (<1.5-fold vs. PBS), no microglial reactivity, and reduced GFAP upregulation.
DC67458 DMT7 DMT7 (pKa 6.5) is an ionizable cationic lipid engineered for co-delivery of mRNA and immunomodulators via LNPs. In 4T1 breast cancer metastasis models, DMT7 LNPs carrying IL-12 mRNA and STING agonist MSA-2 significantly reduce tumor burden and pulmonary metastases while modulating T cell populations. The formulation demonstrates broad immunotherapeutic effects in melanoma models, shifting tumor macrophages toward the M1 phenotype, reducing Tregs, and elevating pro-inflammatory cytokines (IL-12, IL-2, TNF-α, IFN-γ).
DC86120 EA-PIP(LIPID 10) Lipid 10 is a novel ionizable cationic lipid be used for delivery of therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted with Lipid 10-LNP.
DC80068 LIPID PL1 PL1 is a novel biomimetic phospholipid. PL1 nanoparticle delivery of costimulatory receptor CD137 mRNA improved the immunotherapy with an anti-CD137 Ab to some extent in both tumor models with better results obtained in the B16F10 melanoma model as compared to the A20 lymphoma model.
X